

David F Penson

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3631174/david-f-penson-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

440 papers	22,481 citations	68 h-index	142 g-index
685 ext. papers	26,119 ext. citations	3.2 avg, IF	6.69 L-index

#	Paper	IF	Citations
440	Sipuleucel-T immunotherapy for castration-resistant prostate cancer. <i>New England Journal of Medicine</i> , 2010 , 363, 411-22	59.2	3838
439	Update on AUA guideline on the management of benign prostatic hyperplasia. <i>Journal of Urology</i> , 2011 , 185, 1793-803	2.5	786
438	Early detection of prostate cancer: AUA Guideline. <i>Journal of Urology</i> , 2013 , 190, 419-26	2.5	721
437	Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 981-90	9.7	658
436	Long-term functional outcomes after treatment for localized prostate cancer. <i>New England Journal of Medicine</i> , 2013 , 368, 436-45	59.2	639
435	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 479-505	7.3	562
434	Epidemiology and cost of ventral hernia repair: making the case for hernia research. <i>Hernia: the Journal of Hernias and Abdominal Wall Surgery</i> , 2012 , 16, 179-83	3.2	561
433	Overdiagnosis and overtreatment of prostate cancer. <i>European Urology</i> , 2014 , 65, 1046-55	10.2	528
432	Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 1358-67	9.7	493
431	Prostate Cancer, Version 1.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 19-30	7.3	473
430	Adverse effects of androgen deprivation therapy and strategies to mitigate them. <i>European Urology</i> , 2015 , 67, 825-36	10.2	394
429	Nationwide trends in mastectomy for early-stage breast cancer. <i>JAMA Surgery</i> , 2015 , 150, 9-16	5.4	385
428	5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. <i>Journal of Urology</i> , 2005 , 173, 1701-5	2.5	352
427	Prostate cancer and the Will Rogers phenomenon. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 1248-53	9.7	322
426	Quantifying the role of PSA screening in the US prostate cancer mortality decline. <i>Cancer Causes and Control</i> , 2008 , 19, 175-81	2.8	275
425	Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2098-106	2.2	213
424	Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. <i>Cancer</i> , 2006 , 106, 1865-74	6.4	211

423	ICUD-EAU International Consultation on Bladder Cancer 2012: Urinary diversion. <i>European Urology</i> , 2013 , 63, 67-80	10.2	180
422	Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. <i>Journal of Urology</i> , 2005 , 173, 1318-22	2.5	179
421	Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 1126-1140	27.4	177
420	Castration-resistant prostate cancer: AUA Guideline. <i>Journal of Urology</i> , 2013 , 190, 429-38	2.5	174
419	Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. <i>Journal of Urology</i> , 2007 , 177, 1395-400; quiz 1591	2.5	169
418	Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. <i>Diabetes Care</i> , 2003 , 26, 1093-9	14.6	164
417	Laparoscopic partial nephrectomy and prostatectomy: weighing the costs and the benefits. <i>Journal of Urology</i> , 2004 , 172, 6-7	2.5	154
416	Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. <i>Journal of Urology</i> , 2013 , 189, 2039-46	2.5	150
415	General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1147-54	2.2	147
414	Health related quality of life in men with prostate cancer. <i>Journal of Urology</i> , 2003 , 169, 1653-61	2.5	142
413	Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. <i>American Journal of Epidemiology</i> , 2008 , 167, 925-34	3.8	135
412	The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer. <i>Journal of Clinical Epidemiology</i> , 2001 , 54, 350-8	5.7	133
411	Androgen and pituitary control of penile nitric oxide synthase and erectile function in the rat. <i>Biology of Reproduction</i> , 1996 , 55, 567-74	3.9	121
410	Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer. <i>Journal of Urology</i> , 2007 , 177, 876-81; discussion 881-2	2.5	117
409	Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 2197-2206	59.2	114
408	Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 1780-93	9.7	114
407	Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. <i>Annals of Internal Medicine</i> , 2013 , 158, 709-17	8	112
406	Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. <i>Journal of Urology</i> , 2006 , 176, 2025-31; discussion 2031-2	2.5	111

405	Determining cause of death in prostate cancer: are death certificates valid?. <i>Journal of the National Cancer Institute</i> , 2001 , 93, 1822-3	9.7	110
404	13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. <i>Journal of Urology</i> , 2007 , 177, 932-6	2.5	107
403	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. <i>Journal of Clinical Oncology</i> , 2018 , 36, 414-424	2.2	107
402	Quality of life after breast cancer diagnosis and survival. <i>Journal of Clinical Oncology</i> , 2011 , 29, 406-12	2.2	105
401	5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. <i>Journal of Urology</i> , 2008 , 179, S40-4	2.5	102
400	Health related quality of life for men treated for localized prostate cancer with long-term followup. <i>Journal of Urology</i> , 2010 , 183, 2206-12	2.5	101
399	Evaluating localized prostate cancer and identifying candidates for focal therapy. <i>Urology</i> , 2008 , 72, S12-24		101
398	The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. <i>Cancer</i> , 2012 , 118, 5955-63	6.4	100
397	National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. <i>Journal of Urology</i> , 2012 , 187, 816-21	2.5	97
396	Comparison of complications after radical and partial nephrectomy: results from the National Veterans Administration Surgical Quality Improvement Program. <i>BJU International</i> , 2000 , 86, 782-9	5.6	96
395	Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States. <i>Journal of Urology</i> , 2015 , 194, 1587-93	2.5	90
394	Ureteroenteric anastomotic strictures after radical cystectomy-does operative approach matter?. <i>Journal of Urology</i> , 2013 , 189, 541-7	2.5	85
393	Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. <i>Urology</i> , 2004 , 64, 1171-6	1.6	84
392	HEALTH RELATED QUALITY OF LIFE DIFFERENCES BETWEEN BLACK AND WHITE MEN WITH PROSTATE CANCER: DATA FROM THE CANCER OF THE PROSTATE STRATEGIC UROLOGIC RESEARCH ENDEAVOR. <i>Journal of Urology</i> , 2001 , 166, 2281-2285	2.5	84
391	The hemodynamic pathophysiology of impotence following blunt trauma to the erect penis. <i>Journal of Urology</i> , 1992 , 148, 1171-80	2.5	84
390	Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. <i>Journal of Urology</i> , 2005 , 174, 877-81	2.5	82
389	The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 871-7	2.8	80
388	Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. <i>Medical Decision Making</i> , 2008 , 28, 323-31	2.5	80

387	Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1069-74	2.2	79
386	Prostate cancer survivorship care guideline: American Society of Clinical Oncology Clinical Practice Guideline endorsement. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1078-85	2.2	78
385	Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. <i>Journal of Urology</i> , 2011 , 186, 829-34	2.5	78
384	Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 711-8	9.7	74
383	Oxidative stress measured by urine F2-isoprostane level is associated with prostate cancer. <i>Journal of Urology</i> , 2011 , 185, 2102-7	2.5	73
382	The effectiveness of screening for prostate cancer: a nested case-control study. <i>Archives of Internal Medicine</i> , 2006 , 166, 38-43		73
381	Renal cell cancer histological subtype distribution differs by race and sex. <i>BJU International</i> , 2016 , 117, 260-5	5.6	73
380	Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer. <i>Circulation</i> , 2016 , 133, 537-41	16.7	72
379	Epidemiology of stress urinary incontinence in women. <i>Current Urology Reports</i> , 2011 , 12, 370-6	2.9	72
378	NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 19, 134-143	7.3	71
377	Trends in the treatment of localized prostate cancer using supplemented cancer registry data. <i>BJU International</i> , 2011 , 107, 576-84	5.6	70
376	Long-term oncological outcomes in women undergoing radical cystectomy and orthotopic diversion for bladder cancer. <i>Journal of Urology</i> , 2009 , 181, 2052-8; discussion 2058-9	2.5	70
375	Internet health resources and the cancer patient. <i>Cancer Investigation</i> , 2008 , 26, 202-7	2.1	70
374	Urinary functional outcome following radical cystoprostatectomy and ileal neobladder reconstruction in male patients. <i>Journal of Urology</i> , 2013 , 189, 1782-8	2.5	69
373	The association between diffusion of the surgical robot and radical prostatectomy rates. <i>Medical Care</i> , 2011 , 49, 333-9	3.1	68
372	Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. <i>Journal of Urology</i> , 2004 , 171, 2221-5	2.5	68
371	Psychological Impact of Erectile Dysfunction: Validation of a New Health Related Quality of Life Measure for Patients With Erectile Dysfunction. <i>Journal of Urology</i> , 2002 , 168, 2086-2091	2.5	68
370	Survivorship and improving quality of life in men with prostate cancer. <i>European Urology</i> , 2015 , 68, 374-83	10.2	65

369	Recent Changes in Prostate Cancer Screening Practices and Epidemiology. <i>Journal of Urology</i> , 2017 , 198, 1230-1240	2.5	63
368	Effect of intensive glycemic therapy on erectile function in men with type 1 diabetes. <i>Journal of Urology</i> , 2011 , 185, 1828-34	2.5	62
367	Pathological guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature. <i>Journal of Urology</i> , 2007 , 178, 756-60	2.5	61
366	The effect of health insurance status on the treatment and outcomes of patients with colorectal cancer. <i>Journal of Surgical Oncology</i> , 2014 , 110, 227-32	2.8	60
365	Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls. <i>Cancer</i> , 2004 , 101, 2011-9	6.4	60
364	Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach. <i>European Urology</i> , 2015 , 68, 891-8	10.2	59
363	Epidemiology of vocal fold paralyses after total thyroidectomy for well-differentiated thyroid cancer in a Medicare population. <i>Otolaryngology - Head and Neck Surgery</i> , 2014 , 150, 548-57	5.5	59
362	Prostate cancer. <i>Journal of Urology</i> , 2007 , 177, 2020-9	2.5	59
361	Racial/Ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4193-201	2.2	59
360	Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. <i>American Journal of Medicine</i> , 2005 , 118, 850-7	2.4	58
359	Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 149-163	27.4	57
358	Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy. <i>European Urology</i> , 2017 , 72, 712-735	10.2	56
357	Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , 2019 , 20, 556-569	21.7	56
356	Prostate cancer on the Internet--information or misinformation?. <i>Journal of Urology</i> , 2006 , 175, 1836-42; discussion 1842	2.5	56
355	Longitudinal differences in disease specific quality of life in men with erectile dysfunction: results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction study. <i>Journal of Urology</i> , 2003 , 169, 1437-42	2.5	56
354	Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 224-9	12.9	54
353	Clinical and psychosocial characteristics of men with erectile dysfunction: baseline data from ExCEED. <i>Journal of Sexual Medicine</i> , 2006 , 3, 1059-1067	1.1	54
352	Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy. <i>Journal of Urology</i> , 2009 , 182, 2182-7	2.5	53

351	Quality of life after treatment for prostate cancer. <i>Current Urology Reports</i> , 2003 , 4, 185-95	2.9	52
350	Salvage robotic assisted laparoscopic radical prostatectomy: a single institution, 5-year experience. <i>Journal of Urology</i> , 2013 , 189, 507-13	2.5	51
349	Adrenal control of erectile function and nitric oxide synthase in the rat penis. <i>Endocrinology</i> , 1997 , 138, 3925-32	4.8	51
348	Differences in health-related quality of life of prostate cancer patients based on stage of cancer. <i>Psycho-Oncology</i> , 2004 , 13, 800-7	3.9	50
347	Checklist to operationalize measurement characteristics of patient-reported outcome measures. <i>Systematic Reviews</i> , 2016 , 5, 129	3	50
346	Urinary diversion: how experts divert. <i>Urology</i> , 2015 , 85, 233-8	1.6	49
345	Psychometric characteristics of a condition-specific, health-related quality-of-life survey: the FACT-Vanderbilt Cystectomy Index. <i>Urology</i> , 2012 , 80, 77-83	1.6	49
344	Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. <i>Journal of Urology</i> , 2009 , 181, 2214-21; discussion 2221-2	2.5	49
343	How Well Does The Partin Nomogram Predict Pathological Stage After Radical Prostatectomy In A Community Based Population? Results Of The Cancer Of The Prostate Strategic Urological Research Endeavor. <i>Journal of Urology</i> , 2002 , 167, 1653-1658	2.5	49
342	Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 517-526	6.2	48
341	Hospital-Physician Consolidation Accelerated In The Past Decade In Cardiology, Oncology. <i>Health Affairs</i> , 2018 , 37, 1123-1127	7	48
340	Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy. <i>BJU International</i> , 2014 , 113, 894-9	5.6	48
339	Obesity, physical activity and lower urinary tract symptoms: results from the Southern Community Cohort Study. <i>Journal of Urology</i> , 2011 , 186, 2316-22	2.5	48
338	Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. <i>Prostate</i> , 2008 , 68, 1477-86	4.2	48
337	Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2306-2314	2.2	47
336	Effectiveness of hormonal and surgical therapies for cryptorchidism: a systematic review. <i>Pediatrics</i> , 2013 , 131, e1897-907	7.4	46
335	On the importance of race, socioeconomic status and comorbidity when evaluating quality of life in men with prostate cancer. <i>Journal of Urology</i> , 2007 , 177, 1992-9	2.5	46
334	Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. <i>Journal of Urology</i> , 2011 , 186, 2221-7	2.5	45

333	DOES SITE SPECIFIC LABELING OF SEXTANT BIOPSY CORES PREDICT THE SITE OF EXTRACAPSULAR EXTENSION IN RADICAL PROSTATECTOMY SURGICAL SPECIMEN?. <i>Journal of Urology</i> , 1999 , 162, 1352-1357	2.5	44
332	Voice-Related Patient-Reported Outcome Measures: A Systematic Review of Instrument Development and Validation. <i>Journal of Speech, Language, and Hearing Research</i> , 2017 , 60, 62-88	2.8	43
331	Volume outcomes of cystectomy--is it the surgeon or the setting?. <i>Journal of Urology</i> , 2012 , 188, 2139-44.	4.5	43
330	Trends in treatment costs for localized prostate cancer: the healthy screenee effect. <i>Medical Care</i> , 2007 , 45, 154-9	3.1	43
329	The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples. <i>Journal of Urology</i> , 2016 , 195, 321-9	2.5	42
328	Obesity, body composition, and prostate cancer. <i>BMC Cancer</i> , 2012 , 12, 23	4.8	42
327	Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study. <i>Journal of Comparative Effectiveness Research</i> , 2013 , 2, 445-60	2.1	42
326	Sensitivity of Medicare Claims to Identify Cancer Recurrence in Elderly Colorectal and Breast Cancer Patients. <i>Medical Care</i> , 2016 , 54, e47-54	3.1	42
325	Is quality of life different for men with erectile dysfunction and prostate cancer compared to men with erectile dysfunction due to other causes? Results from the ExCEED data base. <i>Journal of Urology</i> , 2003 , 169, 1458-61	2.5	40
324	The Cost-Effectiveness of Treatment for Varicocele Related Infertility. <i>Journal of Urology</i> , 2002 , 168, 2490-2494	2.5	40
323	Prostate Cancer Registries: Current Status and Future Directions. <i>European Urology</i> , 2016 , 69, 998-1012	10.2	39
322	Increasing use of observation among men at low risk for prostate cancer mortality. <i>Journal of Urology</i> , 2015 , 193, 801-6	2.5	39
321	The population level prevalence and correlates of appropriate and inappropriate imaging to stage incident prostate cancer in the medicare population. <i>Journal of Urology</i> , 2012 , 187, 97-102	2.5	38
320	Lymph node yield at radical cystectomy predicts mortality in node-negative and not node-positive patients. <i>Urology</i> , 2012 , 80, 632-40	1.6	38
319	Quality of life issues in bladder cancer patients following cystectomy and urinary diversion. <i>Urologic Clinics of North America</i> , 2005 , 32, 207-16	2.9	38
318	A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III). <i>Journal of Urology</i> , 2019 , 201, 682-692	2.5	38
317	What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 740-50	4	37
316	The Impact of Health Literacy on Surgical Outcomes Following Radical Cystectomy. <i>Journal of Health Communication</i> , 2016 , 21, 99-104	2.5	37

315	Preliminary treatment considerations among men with newly diagnosed prostate cancer. <i>American Journal of Managed Care</i> , 2010 , 16, e121-30	2.1	37
314	Patient-Reported Outcome Measures Related to Laryngopharyngeal Reflux: A Systematic Review of Instrument Development and Validation. <i>Otolaryngology - Head and Neck Surgery</i> , 2016 , 155, 923-935	5.5	35
313	Provider and partner interactions in the treatment decision-making process for newly diagnosed localized prostate cancer. <i>BJU International</i> , 2011 , 108, 851-6; discussion 856-7	5.6	35
312	Invasive T1 bladder cancer: indications and rationale for radical cystectomy. <i>BJU International</i> , 2008 , 102, 270-5	5.6	35
311	Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2019 , 125, 4172-4180	6.4	34
310	Racial variation in the quality of surgical care for bladder cancer. <i>Cancer</i> , 2014 , 120, 1018-25	6.4	34
309	Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions. <i>World Journal of Urology</i> , 2011 , 29, 3-9	4	34
308	Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE. <i>Journal of Urology</i> , 2003 , 170, 905-8	2.5	34
307	Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment. <i>Cancer</i> , 2014 , 120, 1263-71	6.4	33
306	Racial variation in the pattern and quality of care for prostate cancer in the USA: mind the gap. <i>BJU International</i> , 2010 , 106, 322-8	5.6	33
305	Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project. <i>Journal of Urology</i> , 2008 , 180, 520-4; discussion 524	2.5	33
304	Urinary functional outcomes in female neobladder patients. <i>World Journal of Urology</i> , 2014 , 32, 221-8	4	32
303	Twitter response to the United States Preventive Services Task Force recommendations against screening with prostate-specific antigen. <i>BJU International</i> , 2015 , 116, 65-71	5.6	32
302	Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial. <i>Cancer</i> , 2013 , 119, 2223-9	6.4	32
301	An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. <i>American Journal of Epidemiology</i> , 2004 , 160, 1059-69	3.8	32
300	Variation in the intensity of hematuria evaluation: a target for primary care quality improvement. <i>American Journal of Medicine</i> , 2014 , 127, 633-640.e11	2.4	31
299	Appropriate and inappropriate imaging rates for prostate cancer go hand in hand by region, as if set by thermostat. <i>Health Affairs</i> , 2012 , 31, 730-40	7	31
298	Symptoms and inflammation in chronic prostatitis/chronic pelvic pain syndrome. <i>Urology</i> , 2002 , 60, 959-63	3.6	31

297	Assessment of patient experience with unilateral vocal fold immobility: a preliminary study. <i>Journal of Voice</i> , 2014 , 28, 636-43	1.9	30
296	The Effect of Nerve Sparing Status on Sexual and Urinary Function: 3-Year Results from the CEASAR Study. <i>Journal of Urology</i> , 2018 , 199, 1202-1209	2.5	29
295	Magnetic resonance imaging for locating nonpalpable undescended testicles: a meta-analysis. <i>Pediatrics</i> , 2013 , 131, e1908-16	7.4	29
294	Pelvic organ prolapse (POP) surgery: the evidence for the repairs. <i>BJU International</i> , 2011 , 107, 1704-19	5.6	29
293	Regional variation in total cost per radical prostatectomy in the healthcare cost and utilization project nationwide inpatient sample database. <i>Journal of Urology</i> , 2010 , 183, 1504-9	2.5	29
292	Factors influencing patients' acceptance and adherence to active surveillance. <i>Journal of the National Cancer Institute Monographs</i> , 2012 , 2012, 207-12	4.8	29
291	The physical burden of prostate cancer. <i>Urologic Clinics of North America</i> , 2003 , 30, 305-13	2.9	29
290	Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). <i>BJU International</i> , 2013 , 111, 213-20	5.6	28
289	Impact of prostate cancer on sexual relationships: a longitudinal perspective on intimate partners' experiences. <i>Journal of Sexual Medicine</i> , 2013 , 10, 3135-43	1.1	28
288	Erectile aid use by men treated for localized prostate cancer. <i>Journal of Urology</i> , 2009 , 182, 649-54	2.5	28
287	Quality of life after therapy for localized prostate cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2007 , 13, 318-26	2.6	28
286	Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006 , 66, 395-402	4	28
285	The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. <i>Journal of Urology</i> , 2004 , 171, 2250-4	2.5	28
284	Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: results from the CAPSURE database. <i>Urology</i> , 2001 , 57, 499-503	1.6	28
283	The Cancer Survival Query System: making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients. <i>Cancer</i> , 2012 , 118, 5652-62	6.4	27
282	Immediate effects of the initial FDA notification on the use of surgical mesh for pelvic organ prolapse surgery in medicare beneficiaries. <i>Neurourology and Urodynamics</i> , 2013 , 32, 330-5	2.3	27
281	Association between socioeconomic status (SES) and lower urinary tract symptom (LUTS) severity among black and white men. <i>Journal of General Internal Medicine</i> , 2011 , 26, 1305-10	4	27
280	Sexual dysfunction and symptom impact in men with long-standing type 1 diabetes in the DCCT/EDIC cohort. <i>Journal of Sexual Medicine</i> , 2009 , 6, 1969-78	1.1	27

279	Prostate-sparing cystectomy: a review of the oncologic and functional outcomes. Contraindicated in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009 , 27, 466-72 ^{2.8}	2.8	27
278	The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. <i>Journal of Urology</i> , 2005 , 174, 547-52; discussion 552	2.5	27
277	Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis. <i>Urology</i> , 2013 , 82, 327-33	1.6	26
276	Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspective. <i>Supportive Care in Cancer</i> , 2013 , 21, 3461-9	3.9	26
275	Centralization of radical prostatectomy in the United States. <i>Journal of Urology</i> , 2013 , 189, 500-6	2.5	26
274	Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. <i>World Journal of Urology</i> , 2011 , 29, 51-7	4	26
273	Prostate cancer: epidemiology and health-related quality of life. <i>Urology</i> , 2008 , 72, S3-11	1.6	26
272	Perioperative Oral Nutrition Supplementation Reduces Prevalence of Sarcopenia following Radical Cystectomy: Results of a Prospective Randomized Controlled Trial. <i>Journal of Urology</i> , 2019 , 201, 470-477 ⁵	2.75	26
271	Effect of injection augmentation on need for framework surgery in unilateral vocal fold paralysis. <i>Laryngoscope</i> , 2016 , 126, 128-34	3.6	26
270	Gender, race, and variation in the evaluation of microscopic hematuria among Medicare beneficiaries. <i>Journal of General Internal Medicine</i> , 2015 , 30, 440-7	4	25
269	Surgeon Participation in Early Accountable Care Organizations. <i>Annals of Surgery</i> , 2018 , 267, 401-407	7.8	25
268	Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. <i>Annals of Internal Medicine</i> , 2018 , 168, 1-9	8	25
267	Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer. <i>Urology</i> , 2014 , 83, 1309-15	1.6	25
266	Access to information sources and treatment considerations among men with local stage prostate cancer. <i>Urology</i> , 2009 , 74, 509-15	1.6	25
265	Prediction of long-term other-cause mortality in men with early-stage prostate cancer: results from the Prostate Cancer Outcomes Study. <i>Urology</i> , 2015 , 85, 92-100	1.6	24
264	Knowledge of the harms of tobacco use among patients with bladder cancer. <i>Cancer</i> , 2014 , 120, 3914-22 ^{6.4}	6.4	24
263	The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study. <i>Journal of Urology</i> , 2005 , 173, 903-7	2.5	24
262	Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy. <i>Journal of Urology</i> , 2015 , 193, 1226-31	2.5	23

261	Trends in the use of evidence-based therapy for resectable gastric cancer. <i>Journal of Surgical Oncology</i> , 2014 , 110, 285-90	2.8	23
260	Racial variation in the quality of surgical care for prostate cancer. <i>Journal of Urology</i> , 2012 , 188, 1279-85	2.5	23
259	Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results. <i>European Urology</i> , 2018 , 74, 26-33	10.2	21
258	Treatment of a population based sample of men diagnosed with testicular cancer in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009 , 27, 604-10	2.8	21
257	Medicare Accountable Care Organization Enrollment and Appropriateness of Cancer Screening. <i>JAMA Internal Medicine</i> , 2018 , 178, 648-654	11.5	20
256	Longitudinal differences in psychological outcomes for men with erectile dysfunction: results from ExCEED. <i>Journal of Sexual Medicine</i> , 2006 , 3, 1068-1076	1.1	20
255	Quality of life with advanced metastatic prostate cancer. <i>Urologic Clinics of North America</i> , 2012 , 39, 505-15	2.5	19
254	Diabetes mellitus and health-related quality of life in prostate cancer: 5-year results from the Prostate Cancer Outcomes Study. <i>BJU International</i> , 2011 , 107, 1223-31	5.6	19
253	Long-term outcome in patients with a Gleason score ≤ 6 prostate cancer treated by radical prostatectomy. <i>BJU International</i> , 2011 , 108, 660-4	5.6	19
252	Quality of life in patients with localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005 , 23, 208-15	2.8	19
251	A 22 Gene-expression Assay, Decipher [®] (GenomeDx Biosciences) to Predict Five-year Risk of Metastatic Prostate Cancer in Men Treated with Radical Prostatectomy. <i>PLOS Currents</i> , 2015 , 7,		19
250	Prostate cancer survivorship care guidelines: American Society of Clinical Oncology practice guideline endorsement. <i>Journal of Oncology Practice</i> , 2015 , 11, e445-9	3.1	18
249	The development of a telemedical cancer center within the Veterans Affairs Health Care System: a report of preliminary clinical results. <i>Telemedicine Journal and E-Health</i> , 2002 , 8, 123-30	5.9	18
248	Health-related quality of life for men with prostate cancer and diabetes: a longitudinal analysis from CaPSURE. <i>Urology</i> , 2006 , 68, 1242-7	1.6	17
247	Self-Reported Health Status Predicts Other-Cause Mortality in Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study. <i>Journal of General Internal Medicine</i> , 2015 , 30, 924-34	4	16
246	Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer. <i>JAMA Surgery</i> , 2017 , 152, 27-34	5.4	16
245	Comparison of the International Index of Erectile Function erectile domain scores and nocturnal penile tumescence and rigidity measurements: does one predict the other?. <i>BJU International</i> , 2006 , 98, 105-9; discussion 109	5.6	16
244	Lessons learnt about early prostate cancer from large scale databases: population-based pearls of wisdom. <i>Surgical Oncology</i> , 2002 , 11, 3-11	2.5	16

243	Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. <i>Cancer</i> , 2003 , 98, 496-503	6.4	16
242	Racial Variation in the Incidence of Squamous Cell Carcinoma of the Bladder in the United States. <i>Journal of Urology</i> , 2002 , 168, 1960-1963	2.5	16
241	The cost-effectiveness of treatment for varicocele related infertility. <i>Journal of Urology</i> , 2002 , 168, 2490-2495	2.5	16
240	Successful external validation of a model to predict other cause mortality in localized prostate cancer. <i>BMC Medicine</i> , 2016 , 14, 25	11.4	15
239	Patterns and predictors of urodynamics use in the United States. <i>Journal of Urology</i> , 2013 , 189, 1791-6	2.5	15
238	Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study. <i>Journal of Urology</i> , 2007 , 177, 1307-12	2.5	15
237	The comparative oncologic effectiveness of available management strategies for clinically localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 51-58	2.8	14
236	Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study. <i>Journal of Urology</i> , 2017 , 197, 1251-1257	2.5	14
235	Oncologic Outcomes after Anterior Exenteration for Muscle Invasive Bladder Cancer in Women. <i>Journal of Urology</i> , 2016 , 196, 1030-5	2.5	14
234	Variation in the Diagnostic Evaluation among Persons with Hematuria: Influence of Gender, Race and Risk Factors for Bladder Cancer. <i>Journal of Urology</i> , 2017 , 198, 1033-1038	2.5	14
233	Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?. <i>Urology</i> , 2005 , 66, 835-9	1.6	14
232	An update on randomized clinical trials in localized and locoregional prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005 , 23, 280-8	2.8	14
231	Steroid hormones and hormone-related genetic and lifestyle characteristics as risk factors for benign prostatic hyperplasia: review of epidemiologic literature. <i>Urology</i> , 2004 , 64, 201-11	1.6	14
230	TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 286-293	2.8	13
229	Pay for performance: rationale and potential implications for urology. <i>Journal of Urology</i> , 2007 , 178, 402-8	2.5	13
228	The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research. <i>European Urology</i> , 2015 , 67, 1019-1025	10.2	12
227	Decision-making processes among men with low-risk prostate cancer: A survey study. <i>Psycho-Oncology</i> , 2018 , 27, 325-332	3.9	12
226	Impact of complications and hospital-free days on health related quality of life 1 year after radical cystectomy. <i>Journal of Urology</i> , 2014 , 192, 1360-4	2.5	12

225	Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer. <i>Urology</i> , 2013 , 82, 410-5	1.6	12
224	Combining longitudinal studies of PSA. <i>Biostatistics</i> , 2004 , 5, 483-500	3.7	12
223	The Influence of Psychosocial Constructs on the Adherence to Active Surveillance for Localized Prostate Cancer in a Prospective, Population-based Cohort. <i>Urology</i> , 2017 , 103, 173-178	1.6	11
222	The Patient Protection and Affordable Care Act: the impact on urologic cancer care. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 980-4	2.8	11
221	Racial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Results from the CEASAR Study. <i>European Urology</i> , 2017 , 72, 307-314	10.2	11
220	Segmental Testicular Infarction in the Neonate: A Case Report. <i>Journal of Urology</i> , 1995 , 153, 1992-1993	2.5	11
219	Adrenal Control of Erectile Function and Nitric Oxide Synthase in the Rat Penis		11
218	Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. <i>Journal of Urology</i> , 2021 , 205, 769-779	2.5	11
217	Cardiology Patient Page. ABCDE Steps for Heart and Vascular Wellness Following a Prostate Cancer Diagnosis. <i>Circulation</i> , 2015 , 132, e218-20	16.7	10
216	Information Seeking and Satisfaction with Information Sources Among Spouses of Men with Newly Diagnosed Local-Stage Prostate Cancer. <i>Journal of Cancer Education</i> , 2018 , 33, 325-331	1.8	10
215	Doing More for More: Unintended Consequences of Financial Incentives for Oncology Specialty Care. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	10
214	The politics of prostate cancer screening. <i>Urologic Clinics of North America</i> , 2014 , 41, 249-55	2.9	10
213	Choledocholithiasis management in rural America: health disparity or health opportunity?. <i>Journal of Surgical Research</i> , 2011 , 170, 214-9	2.5	10
212	Considering racial and ethnic preferences in communication and interactions among the patient, family member, and physician following diagnosis of localized prostate cancer: study of a US population. <i>International Journal of General Medicine</i> , 2011 , 4, 481-6	2.3	10
211	Effect of cryptorchidism on testicular histology in a naturally cryptorchid animal model. <i>Journal of Urology</i> , 1997 , 158, 1978-82	2.5	10
210	Treatment outcomes in localized prostate cancer: a patient-oriented approach. <i>Urologic Oncology</i> , 2002 , 20, 63-73		10
209	Therapeutic Ultrasound and Prostate Cancer. <i>Seminars in Interventional Radiology</i> , 2017 , 34, 187-200	1.6	10
208	Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to Action. <i>European Urology Oncology</i> , 2021 , 4, 396-404	6.7	10

207	Trends in the multimodality treatment of resectable colorectal liver metastases: an underutilized strategy. <i>Journal of Gastrointestinal Surgery</i> , 2013 , 17, 1938-46	3.3	9
206	Health care reform 2010: a fresh view on tort reform. <i>Journal of Urology</i> , 2010 , 184, 1840-6	2.5	9
205	Unanticipated and underappreciated outcomes during management of local stage prostate cancer: a prospective survey. <i>Journal of Urology</i> , 2010 , 184, 120-5	2.5	9
204	Assessing the quality of prostate cancer care. <i>Current Opinion in Urology</i> , 2008 , 18, 297-302	2.8	9
203	Patient-Reported Outcome Measures in Upper Airway-Related Dyspnea: A Systematic Review. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017 , 143, 824-831	3.9	8
202	Complementary and alternative medicine use, patient-reported outcomes, and treatment satisfaction among men with localized prostate cancer. <i>Urology</i> , 2012 , 79, 1034-41	1.6	8
201	Willingness to pay for prostate cancer treatment among patients and their family members at 1 year after diagnosis. <i>Value in Health</i> , 2012 , 15, 716-23	3.3	8
200	Comparative effectiveness research in localized prostate cancer treatment. <i>Journal of Comparative Effectiveness Research</i> , 2013 , 2, 583-93	2.1	8
199	Computer-generated graphical presentations: use of multimedia to enhance communication. <i>Urology</i> , 1997 , 49, 2-9	1.6	8
198	Impact of Adherence to Quality Measures for Localized Prostate Cancer on Patient-reported Health-related Quality of Life Outcomes, Patient Satisfaction, and Treatment-related Complications. <i>Medical Care</i> , 2016 , 54, 738-44	3.1	8
197	How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the cancer of the prostate strategic urological research endeavor. <i>Journal of Urology</i> , 2002 , 167, 1653-7; discussion 1657-8	2.5	8
196	Urinary retention and catheter use among U.S. female Medicare beneficiaries: Prevalence and risk factors. <i>Neurourology and Urodynamics</i> , 2017 , 36, 2101-2108	2.3	7
195	Predictors of Response Outcomes for Research Recruitment Through a Central Cancer Registry: Evidence From 17 Recruitment Efforts for Population-Based Studies. <i>American Journal of Epidemiology</i> , 2019 , 188, 928-939	3.8	7
194	Interpretation of Domain Scores on the EPIC-How Does the Domain Score Translate into Functional Outcomes?. <i>Journal of Urology</i> , 2019 , 202, 1150-1158	2.5	7
193	Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts. <i>Cancer</i> , 2020 , 126, 583-592	6.4	7
192	Cost-effective management of pelvic fracture urethral injuries. <i>World Journal of Urology</i> , 2017 , 35, 1617-1623	4.6	6
191	Trends in urodynamics in U.S. female medicare beneficiaries, 2000-2010. <i>Neurourology and Urodynamics</i> , 2015 , 34, 420-3	2.3	6
190	Benchmarking the use of a rapid response team by surgical services at a tertiary care hospital. <i>Journal of the American College of Surgeons</i> , 2014 , 218, 66-72	4.4	6

189	Functional outcomes after treatment for prostate cancer. <i>New England Journal of Medicine</i> , 2013 , 368, 1654	59.2	6
188	Outpatient versus inpatient observation after percutaneous native kidney biopsy: a cost minimization study. <i>American Journal of Nephrology</i> , 2011 , 34, 64-70	4.6	6
187	Pharmacoeconomics of available treatment options for metastatic prostate cancer. <i>Pharmacoeconomics</i> , 2007 , 25, 309-27	4.4	6
186	Quality of life following prostate cancer treatments. <i>Current Urology Reports</i> , 2000 , 1, 71-7	2.9	6
185	Patient-Reported Financial Toxicity Associated with Contemporary Treatment for Localized Prostate Cancer. <i>Journal of Urology</i> , 2021 , 205, 761-768	2.5	6
184	Modeling economic and epidemiological impact of voluntary medical male circumcision among men who have sex with men in Beijing, China. <i>International Journal of STD and AIDS</i> , 2019 , 30, 630-638	1.4	5
183	Fibromyxoid Nephrogenic Adenoma in the Ureter. <i>Journal of Endourology Case Reports</i> , 2018 , 4, 97-99	0.3	5
182	Comparison of Patient-reported Outcomes After External Beam Radiation Therapy and Combined External Beam With Low-dose-rate Brachytherapy Boost in Men With Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 102, 116-126	4	5
181	Selecting Active Surveillance: Decision Making Factors for Men with a Low-Risk Prostate Cancer. <i>Medical Decision Making</i> , 2019 , 39, 962-974	2.5	5
180	Physicians' perspectives on the informational needs of low-risk prostate cancer patients. <i>Health Education Research</i> , 2017 , 32, 134-152	1.8	5
179	Comparison of open live donor nephrectomy, laparoscopic live donor nephrectomy, and hand-assisted live donor nephrectomy: a cost-minimization analysis. <i>Journal of Surgical Research</i> , 2012 , 176, e89-94	2.5	5
178	Canadian Consensus Conference: The FDA decision on the use of 5ARIs. <i>Canadian Urological Association Journal</i> , 2012 , 6, 83-8	1.2	5
177	Patient recruitment methods to evaluate treatment decision making for localized prostate cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010 , 33, 381-6	2.7	5
176	Association of Preexisting Symptoms with Treatment Decisions among Newly Diagnosed Prostate Cancer Patients. <i>Patient</i> , 2008 , 1, 189	3.7	5
175	Variations in prostate cancer patterns of care: is it the quality of care or the quality of the data?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7783-4	2.2	5
174	Patient-Reported Outcome Measures in Colon and Rectal Surgery: A Systematic Review and Quality Assessment. <i>Diseases of the Colon and Rectum</i> , 2020 , 63, 1156-1167	3.1	5
173	Racial disparities in mortality for patients with prostate cancer after radical prostatectomy. <i>Cancer</i> , 2021 , 127, 1517-1528	6.4	5
172	The association between Medicare accountable care organization enrollment and breast, colorectal, and prostate cancer screening. <i>Cancer</i> , 2018 , 124, 4366-4373	6.4	5

171	Racial variation in receipt of quality radiation therapy for prostate cancer. <i>Cancer Causes and Control</i> , 2018 , 29, 895-899	2.8	5
170	Contemporary prostate cancer radiation therapy in the United States: Patterns of care and compliance with quality measures. <i>Practical Radiation Oncology</i> , 2018 , 8, 307-316	2.8	5
169	What Do Men with Metastatic Prostate Cancer Consider When Making Treatment Decisions? A Mixed-methods Study. <i>Patient Preference and Adherence</i> , 2020 , 14, 1949-1959	2.4	4
168	Development and Internal Validation of a Web-based Tool to Predict Sexual, Urinary, and Bowel Function Longitudinally After Radiation Therapy, Surgery, or Observation. <i>European Urology</i> , 2020 , 78, 248-255	10.2	4
167	Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research. <i>Future Oncology</i> , 2016 , 12, 2689-2699	3.6	4
166	Re: Changes in Burnout and Satisfaction with Work-Life Balance in Physicians and the General US Working Population between 2011 and 2014. <i>Journal of Urology</i> , 2016 , 195, 1568	2.5	4
165	Adoption of Intermittent Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study in American Urology Practice. <i>Urology Practice</i> , 2015 , 2, 190-198	0.8	4
164	Effect of age, tumor risk, and comorbidity in a u.s. Population-based cohort of men with prostate cancer. <i>Annals of Internal Medicine</i> , 2013 , 159, 370	8	4
163	The invasive T1 bladder tumor: contemporary issues and rationale for radical cystectomy. <i>Current Urology Reports</i> , 2008 , 9, 179-81	2.9	4
162	Men's health: are we missing the big picture?. <i>Journal of General Internal Medicine</i> , 2001 , 16, 717-8	4	4
161	Health-related quality of life (HRQoL) deterioration and pain progression in men with non-metastatic castration-resistant prostate cancer (M0 CRPC): Results from the PROSPER study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5010-5010	2.2	4
160	Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5035-5035	2.2	4
159	Assessing the Quality of Surgical Care for Clinically Localized Prostate Cancer: Results from the CEASAR Study. <i>Journal of Urology</i> , 2020 , 204, 1236-1241	2.5	4
158	Anticipating the Unintended Consequences of Closing the Door on Physician Self-Referral. <i>Journal of Urology</i> , 2016 , 196, 444-50	2.5	3
157	Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. <i>Cancer</i> , 2019 , 125, 3853-3863	6.4	3
156	An Empiric Evaluation of the Effect of Variation in Intensity of Followup for Surgically Treated Renal Neoplasms on Cancer Specific Survival. <i>Journal of Urology</i> , 2017 , 197, 37-43	2.5	3
155	755 URINARY FUNCTION EVALUATION IN FEMALE CYSTECTOMY PATIENTS WITH ORTHOTOPIC DIVERSION UTILISING A VALIDATED HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE. <i>Journal of Urology</i> , 2010 , 183,	2.5	3
154	National Variation in Elective Colon Resection for Diverticular Disease. <i>Annals of Surgery</i> , 2020 , 275,	7.8	3

153	COVID-19 and financial toxicity in patients with renal cell carcinoma. <i>World Journal of Urology</i> , 2021 , 39, 2559-2565	4	3
152	Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?. <i>Journal of Clinical Oncology</i> , 2018 , 36, 937-941	2.2	3
151	Active surveillance: not your father's watchful waiting. <i>Oncology</i> , 2009 , 23, 980, 982	1.8	3
150	Patient expectations of benefit from systemic treatments for metastatic prostate cancer. <i>Cancer Medicine</i> , 2020 , 9, 980-987	4.8	2
149	Re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>Eur Urol</i> 2018;73:262-70. <i>European Urology</i> , 2018 , 73, e98-e99	10.2	2
148	Re: Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer. <i>Journal of Urology</i> , 2016 , 196, 352-4	2.5	2
147	Re: Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2016 , 195, 353	2.5	2
146	Re: urologists' use of intensity-modulated radiation therapy for prostate cancer. <i>Journal of Urology</i> , 2014 , 191, 1292	2.5	2
145	Vasculogenic Erectile Dysfunction 2013 , 341-348		2
144	Use of prostate-specific antigen in the follow-up of patients with localized prostate cancer: results of a nationwide survey of urologists. <i>Urology</i> , 2006 , 68, 80-4	1.6	2
143	Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. <i>European Journal of Cancer</i> , 2021 , 159, 237-246	7.5	2
142	Functional Recovery Following Primary Treatment for Prostate Cancer: Update from the CEASAR Study. <i>European Urology Focus</i> , 2020 , 6, 205-207	5.1	2
141	MR Imaging-Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer: Preliminary Experience from a Single Center in a Prospective, Multi-Center, Single-Arm Clinical Trial. <i>Journal of Vascular and Interventional Radiology</i> , 2020 , 31, 740-746.e4	2.4	2
140	Re: Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. <i>Journal of Urology</i> , 2016 , 196, 105-6	2.5	2
139	Re: Annual Medical Expenditure and Productivity Loss among Colorectal, Female Breast, and Prostate Cancer Survivors in the United States. <i>Journal of Urology</i> , 2016 , 196, 105	2.5	2
138	Editorial Comment. <i>Urology</i> , 2016 , 95, 3-4	1.6	2
137	Adverse Events Associated with Cumulative Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis. <i>Drug Safety</i> , 2020 , 43, 23-33	5.1	2
136	A comparison of general, genitourinary, bowel, and sexual quality of life among long term survivors of prostate, bladder, colorectal, and lung cancer. <i>Journal of Geriatric Oncology</i> , 2021 , 12, 305-311	3.6	2

135	The Impact of Hospital Volume on Short-term and Long-term Outcomes for Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2021 , 147, 135-142	1.6	2
134	Re: Impact of Hair Removal on Surgical Site Infection Rates: A Prospective Randomized Noninferiority Trial. <i>Journal of Urology</i> , 2017 , 197, 1462-1463	2.5	1
133	Re: Effect of insurance expansion on utilization of inpatient surgery. <i>Journal of Urology</i> , 2015 , 193, 256	2.5	1
132	Reply to M.A.N. Endur et al and J. Michels. <i>Journal of Clinical Oncology</i> , 2017 , 35, 123	2.2	1
131	Considering quantity and quality of life in metastatic castration-naive prostate cancer. <i>Lancet Oncology</i> , 2018 , 19, 153-154	21.7	1
130	Re: Trends in Management for Patients with Localized Prostate Cancer, 1990-2013. <i>Journal of Urology</i> , 2016 , 195, 353-4	2.5	1
129	Re: Comparative Effectiveness of Robot-Assisted and Open Radical Prostatectomy in the Postdissemination Era. <i>Journal of Urology</i> , 2014 , 192, 1421-1423	2.5	1
128	The hidden agenda in the release of the Medicare physician reimbursement data. <i>Urology</i> , 2014 , 84, 501-26		1
127	The Influence of Access Related Factors on Adherence to Clinical Practice Guidelines for Muscle Invasive Bladder Cancer. <i>Urology Practice</i> , 2014 , 1, 127-133	0.8	1
126	Re: variation in surgical-readmission rates and quality of hospital care. <i>Journal of Urology</i> , 2014 , 191, 1363-4	2.5	1
125	Re: Black patients more likely than whites to undergo surgery at low-quality hospitals in segregated regions. <i>Journal of Urology</i> , 2013 , 190, 2211	2.5	1
124	MP27-11 DISTINCT SIDE EFFECT PROFILES AFTER CONTEMPORARY TREATMENT OF LOCALIZED PROSTATE CANCER. <i>Journal of Urology</i> , 2015 , 193,	2.5	1
123	The more, the merrier: including a medical oncologist in treatment planning for localized prostate cancer. <i>Journal of Oncology Practice</i> , 2014 , 10, 113-4	3.1	1
122	Re: association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. <i>Journal of Urology</i> , 2014 , 192, 177-8	2.5	1
121	Systemic therapy and the urologic oncologist: a unique opportunity for the specialty to provide comprehensive care that ultimately benefits the patient. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012 , 30, S2-4	2.8	1
120	Socioeconomic factors, urological epidemiology and practice patterns. <i>Journal of Urology</i> , 2010 , 184, 1991-4	2.5	1
119	Treatment for postprostatectomy incontinence: is this as good as it gets?. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 197-8	27.4	1
118	Adhering to the standard of care for prostate cancer. <i>Health Affairs</i> , 2012 , 31, 1367; author reply 1367	7	1

117	Cost-effectiveness of prostate cancer chemoprevention: A quality of life-years analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008 , 26, 564-565	2.8	1
116	Quality of life and satisfaction with outcome among prostate-cancer survivors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008 , 26, 565-566	2.8	1
115	Health-related quality of life results in pathologic Stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008 , 26, 567-568	2.8	1
114	Discussing quality-of-life issues with a patient newly diagnosed with prostate cancer. <i>Nature Reviews Urology</i> , 2006 , 3, 449-52		1
113	Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer: Litwin MS, Gore JL, Kwan L, Brandeis JM, Lee SP, Withers HR, Reiter RE, Department of Urology, David Geffen School of Medicine at UCLA, University of California-Los Angeles, Los Angeles, CA. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007 , 25, 442-443	2.8	1
112	Male Sexual Function: A Guide to Clinical Management. <i>Annals of Internal Medicine</i> , 2002 , 137, 300	8	1
111	Patient expectations from systemic treatment of metastatic prostate cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 218-218	2.2	1
110	Cerebrovascular event (CVE) outcome and overall survival (OS) in patients (pts) treated with sipuleucel-T (sip-T) for metastatic castration-resistant prostate cancer (mCRPC): results from the PROCEED registry.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e17018-e17018	2.2	1
109	Association Between Treatment for Localized Prostate Cancer and Mental Health Outcomes.. <i>Journal of Urology</i> , 2022 , 101097JU000000000000002370	2.5	1
108	Association between health-related quality of life (HRQoL) and clinical outcomes in non-metastatic castration-resistant prostate cancer (M0 CRPC): Results from the PROSPER study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5043-5043	2.2	1
107	Osteoclast inhibitor treatment among men with metastatic castration-resistant prostate cancer. <i>Clinical Oncology and Research</i> , 2018 , 1, 2-7	0.9	1
106	Assessing Quality of Life 2000 , 183-198		1
105	The Impact of Prostate Cancer Diagnosis and Post-treatment Sexual Dysfunction on Quality of Life 2009 , 17-32		1
104	The Cost-Effectiveness of Treatment for Varicocele Related Infertility. <i>Journal of Urology</i> , 2002 , 2490-2494	2.4	1
103	Real-world study of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or abiraterone acetate plus prednisone (AA+P): Patient characteristics and treatment persistence.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16542-e16542	2.2	1
102	Radiotherapy after radical prostatectomy: Effect of timing of postprostatectomy radiation on functional outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 930.e23-930.e32	2.8	1
101	Reply by Authors. <i>Journal of Urology</i> , 2021 , 205, 779	2.5	1
100	Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer. <i>Cancer</i> , 2021 , 127, 1912-1925	6.4	1

99	Patient Reported Comparative Effectiveness of Contemporary Intensity Modulated Radiation Therapy Versus External Beam Radiation Therapy of the Mid 1990s for Localized Prostate Cancer. <i>Urology Practice</i> , 2018 , 5, 471-479	0.8	1
98	Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials. <i>BMC Urology</i> , 2018 , 18, 77	2.2	1
97	Quality of life after treatment for prostate cancer. <i>Current Prostate Reports</i> , 2003 , 1, 55-65		0
96	The prevention of extraction site incisional hernia after robotic-assisted radical prostatectomy. <i>Journal of Robotic Surgery</i> , 2021 , 15, 315-317	2.9	0
95	PROSPER subgroup analysis by age and region: Overall survival and safety in men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy plus enzalutamide.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 84-84	2.2	0
94	Out-of-pocket costs for commercially insured patients with localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 797-805	2.8	0
93	Differential effect of body mass index by gender on oncological outcomes in patients with renal cell carcinoma. <i>Journal of Cancer Research and Therapeutics</i> , 2021 , 17, 420-425	1.2	0
92	Re: Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer. <i>Journal of Urology</i> , 2017 , 197, 401-402	2.5	
91	Re: Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. <i>Journal of Urology</i> , 2017 , 197, 702-704	2.5	
90	Re: Active Surveillance of Prostate Cancer in a Community Practice: How to Measure, Manage, and Improve?. <i>Journal of Urology</i> , 2017 , 197, 703	2.5	
89	Re: Association of Androgen Deprivation Therapy with Depression in Localized Prostate Cancer. <i>Journal of Urology</i> , 2017 , 197, 703-704	2.5	
88	Re: Vasectomy and Prostate Cancer Incidence and Mortality in a Large US Cohort. <i>Journal of Urology</i> , 2017 , 198, 104-106	2.5	
87	Re: Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States. <i>Journal of Urology</i> , 2017 , 198, 104-105	2.5	
86	Re: Projecting the Urology Workforce over the Next 20 Years. <i>Journal of Urology</i> , 2017 , 197, 1339	2.5	
85	Re: Exploring the Burden of Inpatient Readmissions after Major Cancer Surgery. <i>Journal of Urology</i> , 2015 , 194, 1068	2.5	
84	Re: Procedures take less time at ambulatory surgery centers, keeping costs down and ability to meet demand up. <i>Journal of Urology</i> , 2015 , 193, 257-8	2.5	
83	Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data. <i>Cancer</i> , 2020 , 126, 2935-2937	6.4	
82	Reply to I.E. Haines. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1626-1627	2.2	

- 81 Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET. *Future Oncology*, **2018**, 14, 527-536 3.6
- 80 Re: Narrow Networks on the Health Insurance Marketplaces: Prevalence, Pricing, and the Cost of Network Breadth. *Journal of Urology*, **2018**, 199, 883-884 2.5
- 79 Re: Strategies for Identifying and Closing the Gender Salary Gap in Surgery. *Journal of Urology*, **2018**, 199, 332-334 2.5
- 78 Editorial Comment. *Journal of Urology*, **2018**, 199, 1232 2.5
- 77 Re: Oncologic Surveillance after Surgical Resection for Renal Cell Carcinoma: A Novel Risk-Based Approach. *Journal of Urology*, **2016**, 195, 1720 2.5
- 76 Clinical trials in urology **2018**, 19-24
- 75 Re: Introduction of Surgical Safety Checklists in Ontario, Canada. *Journal of Urology*, **2014**, 192, 1146-1147 2.5
- 74 The Impact of Gender on Use of Pelvic Lymphadenectomy at the Time of Radical Cystectomy. *Urology Practice*, **2014**, 1, 146-150 0.8
- 73 Re: Physicians' Attitudes about Multiplex Tumor Genomic Testing. *Journal of Urology*, **2014**, 192, 1422-1423 2.5
- 72 Re: public financing of the Medicare program will make its uniform structure increasingly costly to sustain. *Journal of Urology*, **2014**, 191, 436-7 2.5
- 71 Re: surgical skill and complication rates after bariatric surgery. *Journal of Urology*, **2014**, 191, 437-8 2.5
- 70 Re: Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. *Journal of Urology*, **2014**, 192, 422-3 2.5
- 69 Re: use of statins and the risk of death in patients with prostate cancer. *Journal of Urology*, **2014**, 191, 1288-9 2.5
- 68 Re: Active surveillance for prostate cancer compared with immediate treatment: an economic analysis. *Journal of Urology*, **2013**, 189, 2109-10 2.5
- 67 Capsule commentary on Shahinian et al.: Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer. *Journal of General Internal Medicine*, **2013**, 28, 1494 4
- 66 Re: Explaining racial differences in prostate cancer mortality. *Journal of Urology*, **2013**, 189, 2109 2.5
- 65 Re: Decision aids: when 'nudging' patients to make a particular choice is more ethical than balanced, nondirective content. *Journal of Urology*, **2013**, 190, 1251 2.5
- 64 Re: Primary prevention of nephrolithiasis is cost-effective for a national healthcare system. *Journal of Urology*, **2013**, 190, 902 2.5

63	Re: Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation. <i>Journal of Urology</i> , 2013 , 190, 988-9	2.5
62	Re: a simulation shows limited savings from meeting quality targets under the medicare shared savings program. <i>Journal of Urology</i> , 2013 , 189, 1481-2	2.5
61	Re: Characteristics of persons with overactive bladder of presumed neurologic origin: results from the Boston Area Community Health (BACH) survey. <i>Journal of Urology</i> , 2013 , 190, 977	2.5
60	Re: Socioeconomic status, healthcare density, and risk of prostate cancer among African American and Caucasian men in a large prospective study. <i>Journal of Urology</i> , 2013 , 189, 2108	2.5
59	Re: fee-for-service will remain a feature of major payment reforms, requiring more changes in medicare physician payment. <i>Journal of Urology</i> , 2013 , 189, 1482-3	2.5
58	Re: Certificate of need regulations and the diffusion of intensity-modulated radiotherapy. <i>Journal of Urology</i> , 2013 , 190, 1250-1	2.5
57	Re: Prostate specific antigen testing policy worldwide varies greatly and seems not to be in accordance with guidelines: a systematic review. <i>Journal of Urology</i> , 2013 , 190, 1766	2.5
56	Re: Low-Volume vs High-Volume Centers and Management of Fournier's Gangrene in Washington State. <i>Journal of Urology</i> , 2017 , 198, 248	2.5
55	Re: Preoperative Frailty Predicts Postoperative Complications and Mortality in Urology Patients. <i>Journal of Urology</i> , 2017 , 198, 474	2.5
54	Re: Short-Form Charlson Comorbidity Index for Assessment of Perioperative Mortality after Radical Cystectomy. <i>Journal of Urology</i> , 2017 , 198, 474-475	2.5
53	Re: Association between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes after 3 Years. <i>Journal of Urology</i> , 2017 , 198, 744-745	2.5
52	Re: A Comparison of Web-Based versus Print-Based Decision Aids for Prostate Cancer Screening: Participants' Evaluation and Utilization. <i>Journal of Urology</i> , 2017 , 197, 154	2.5
51	Re: Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer. <i>Journal of Urology</i> , 2017 , 197, 153-154	2.5
50	Trial Design Issues in the Study of Focal Therapy in Prostate and Kidney Cancer 2017 , 233-241	
49	Re: Association of Hospital Participation in a Quality Reporting Program with Surgical Outcomes and Expenditures for Medicare Beneficiaries. <i>Journal of Urology</i> , 2015 , 194, 1068-9	2.5
48	Re: Long-term effect of hospital pay for performance on mortality in England. <i>Journal of Urology</i> , 2015 , 193, 953-4	2.5
47	Re: Ultrasonography versus computed tomography for suspected nephrolithiasis. <i>Journal of Urology</i> , 2015 , 193, 899	2.5
46	Response. <i>Journal of the National Cancer Institute</i> , 2014 , 106, djt466	9.7

- 45 Re: variation among primary care physicians in prostate-specific antigen screening of older men. *Journal of Urology*, **2014**, 191, 1291-2 2.5
- 44 Learning to see the forest through the trees. *Surgery*, **2014**, 155, 797-8 3.6
- 43 Re: value-based insurance design: quality improvement but no cost savings. *Journal of Urology*, **2014**, 191, 761-2 2.5
- 42 Re: Surgical site infections following ambulatory surgery procedures. *Journal of Urology*, **2014**, 192, 431-2.5
- 41 Trends in Care Delivery for Disorders of the Female Pelvic Floor. *Current Bladder Dysfunction Reports*, **2012**, 7, 194-200 0.4
- 40 Re: Temporal national trends of minimally invasive and retropubic radical prostatectomy outcomes from 2003 to 2007: results from the 100% Medicare sample. *Journal of Urology*, **2013**, 189, 125-6 2.5
- 39 Accountable care organizations in surgery: location, location, location: Comment on "will accountable care organizations cut costs and improve quality for inpatient surgery?". *JAMA Surgery*, **2013**, 148, 554 5.4
- 38 Re: The Practice of Imaging Self-Referral Doesn't Produce Much One-Stop Service. *Journal of Urology*, **2011**, 185, 2288-2288 2.5
- 37 Urology Board ReviewLeslieS.W.: Urology Board Review. New York: McGraw Hill Medical2009. 521 pages.. *Journal of Urology*, **2010**, 183, 2473-2473 2.5
- 36 Clinical Trials in Urology **2010**, 12-17
- 35 Re: Acquisition of MRI Equipment by Doctors Drives up Imaging Use and Spending. *Journal of Urology*, **2011**, 185, 2289-2290 2.5
- 34 Ethical Issues in Clinical Research **2006**, 31-46
- 33 Survival associated with treatment vs. observation of localized prostate cancer in elderly men: Wong YN, Mitra N, Hudes G, Localio R, Schwartz JS, Wan F, Montagnet C, Armstrong K, Division of Population Science, Fox Chase Cancer Center, Philadelphia, PA. *Urologic Oncology: Seminars and Original Investigations*, **2007**, 25, 440-441 2.8
- 32 On the importance of race, socioeconomic status, and comorbidity when evaluating quality of life in men with prostate cancer: Ramsey SD, Zeliadt SB, Hall IJ, Ekwueme DU, Penson DF, Fred Hutchinson Cancer Research Center, Seattle, WA. *Urologic Oncology: Seminars and Original Investigations*, **2007**, 25, 441-442 2.8
- 31 Men's health. *Journal of General Internal Medicine*, **2001**, 16, 717-718 4
- 30 A Modest Proposal: Prostate Biopsies and In-house Pathology Laboratories. *Reviews in Urology*, **2013**, 15, 135-6 1
- 29 Quality-of-Life Issues in Incontinence **2004**, 53-64
- 28 Comparison of enzalutamide and bicalutamide in patients with non-metastatic castration-resistant prostate cancer: Number needed to treat to achieve one additional patient free of clinical progression events.. *Journal of Clinical Oncology*, **2018**, 36, 228-228 2.2

27	Impact of enzalutamide (ENZA) vs. bicalutamide (BIC) on health-related quality of life (HRQoL) of patients (pts) with castration-resistant prostate cancer (CRPC): STRIVE study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 234-234	2.2
26	Do accountable care organizations affect race mediated differences in cancer screening?. <i>Journal of Clinical Oncology</i> , 2018 , 36, 131-131	2.2
25	Sipuleucel-T (sip-T) overall survival (OS) and clinical outcomes by baseline (BL) prostate-specific antigen (PSA) quartiles in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROCEED registry.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5041-5041	2.2
24	Influence of facility (Fac) annual caseload (AC) on survival of patients (pts) with respectable urothelial carcinoma (UC) of the bladder.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16513-e16513	2.2
23	Clinical events associated with cumulative corticosteroid use in patients with castration-resistant prostate cancer: An administrative claims analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 236-236	2.2
22	Cognitive effects of androgen receptor (AR) directed therapies for advanced cancer of the prostate (COGCaP).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS5098-TPS5098	2.2
21	Editorial Comment. <i>Journal of Urology</i> , 2019 , 202, 972	2.5
20	Influence of age on incident diabetes (DM) and cardiovascular disease (CVD) among prostate cancer survivors receiving androgen deprivation therapy (ADT).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6583-6583	2.2
19	Time to chemotherapy following treatment with sipuleucel-T: Data from PROCEED.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5040-5040	2.2
18	Creation of a standardized set of patient-centered outcomes for advanced prostate cancer: An international effort.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 282-282	2.2
17	Bisphosphonate utilization among men with metastatic castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16088-e16088	2.2
16	Changing characteristics of patients treated with sipuleucel-T (sip-T) over time: Real-world experience from the PROCEED registry.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 320-320	2.2
15	The TRUMPET registry: Assessing clinical outcomes and quality of life in patients with castration-resistant prostate cancer and their caregivers.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 241-241 ^{2.2}	2.2
14	Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) in oncology (ONC) urology (URO) practices: Data from the PROCEED registry.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16503-e16503 ^{2.2}	2.2
13	Relationship between smoking, prognostic factors, and outcomes in patient (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving sipuleucel-T (sip-T): Preliminary analysis of the PROCEED registry.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 216-216	2.2
12	The association of BMI and PSA density on survival among patients with metastatic or castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 207-207	2.2
11	Validation of the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer (CRPC): Data from TRUMPET.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 256-256	2.2
10	Changing trends in pelvic lymphadenectomy in radical prostatectomy with the advent of robotic surgery.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 39-39	2.2

- 9 Bone health among prostate cancer survivors: Long-term follow-up from the Prostate Cancer Outcomes Study (PCOS).. *Journal of Clinical Oncology*, **2013**, 31, 106-106 2.2
- 8 Sensitivity of Medicare claims to identify recurrence.. *Journal of Clinical Oncology*, **2013**, 31, 6522-6522 2.2
- 7 Introduction of a tobacco-screening initiative for those at risk for bladder cancer in a high volume urology clinic.. *Journal of Clinical Oncology*, **2013**, 31, 4540-4540 2.2
- 6 Influence of age on incident diabetes (DM) and cardiovascular disease (CVD) among prostate cancer survivors receiving androgen deprivation therapy (ADT).. *Journal of Clinical Oncology*, **2014**, 32, 31-31 2.2
- 5 Editorial Comment. *Journal of Urology*, **2021**, 205, 1646 2.5
- 4 Association between pelvic nodal radiotherapy and patient-reported functional outcomes through 5 years among men undergoing external-beam radiotherapy for prostate cancer: An assessment of the comparative effectiveness analysis of surgery and radiation (CEASAR) cohort. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 29, 561-564 2.8
- 3 Re: National Prostate Cancer Screening Rates after the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening. *Journal of Urology*, **2016**, 195, 928-9 2.5
- 2 Re: Long Term Safety of Sacral Nerve Modulation in Medicare Beneficiaries. *Journal of Urology*, **2016**, 196, 1504 2.5
- 1 Benchmarking patient satisfaction scores in a colorectal patient population. *Surgical Endoscopy and Other Interventional Techniques*, **2021**, 35, 309-316 5.2